Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States.

@article{Rodriguez2007ConcomitantUO,
  title={Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States.},
  author={Zoe M Rodriguez and Michelle Gail Goveia and Jon E. Stek and Michael J Dallas and John W Boslego and Mark J Dinubile and Penny M. Heaton},
  journal={The Pediatric infectious disease journal},
  year={2007},
  volume={26 3},
  pages={221-7}
}
BACKGROUND A live pentavalent rotavirus vaccine (PRV) containing 5 human-bovine (WC3) reassortants expressing human serotypes G1, G2, G3, G4 and P1A[8] was evaluated in a blinded, placebo-controlled study. Possible interactions between PRV and concomitantly administered licensed pediatric vaccines were investigated in a United States-based nested substudy (Concomitant Use Study) of the Rotavirus Efficacy and Safety Trial. METHODS From 2002 to 2003, healthy infants approximately 6 to 12 weeks… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…